intermittent fasting and semaglutide — what does the best available evidence actually say? ✓ Weight & fat loss ✓ Improved insulin sensitivity ✓ Better lipid profile ⚖️ Mostly mild side effects ❓ Long-term safety Can you combine intermittent fasting

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown even greater efficacy in some studies, with weight reductions of approximately 20% in the SURMOUNT-1 trial

Another important white space is represented by the emergence of comorbidity-driven positioning of oral obesity drugs, which allows marketing such medicines as treatment not only for weight loss but also for obesity associated with type 2 diabetes, cardiovascular risks, metabolic syndrome, and MASH

By activating GLP-1 receptors in multiple areas particularly the hypothalamus and vagus nerve this therapy helps reduce appetite, improve glycaemic control, and support healthier eating behaviours

Every nutritional strategy for GLP-1 therapy flows from these physiological realities